Benitec Biopharma Inc. — Form 8-K
Filed September 24, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Baker Tilly US, LLP resigned as Benitec Biopharma's independent registered public accounting firm effective September 24, 2026. The firm confirmed agreement with the Company's Item 4.01 disclosure regarding the change. No successor auditor has been named in this filing, and no disagreements or audit issues are mentioned.
Why this rating
Auditor changes are routine but require replacement; no disclosed disagreements mitigate concern. Modest negative until successor identified and transition completed.
Extracted items
See more from September 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.